Inhibition of p53 Transcriptional Activity by Bcl-2 Requires Its Membrane-anchoring Domain*

Barbara A. FroeschDagger , Christine Aimé-SempéDagger , Brian Leber§, David Andrews, and John C. ReedDagger parallel

From the Dagger  Burnham Institute, La Jolla, California 92037 and the Departments of § Medicine and  Biochemistry, McMaster University, Hamilton, Ontario, Canada

    ABSTRACT
Top
Abstract
Introduction
References

We show here that the anti-apoptosis protein Bcl-2 potently inhibits p53-dependent transcriptional activation of various p53-responsive promoters in reporter gene co-transfection assays in human embryonic kidney 293 and MCF7 cells, without affecting nuclear accumulation of p53 protein. In contrast, Bcl-2(Delta transmembrane (TM)), which lacks a hydrophobic membrane-anchoring domain, had no effect on p53 activity. Similarly, in MCF7 cells stably expressing either Bcl-2 or Bcl-2(Delta TM), nuclear levels of p53 protein were up-regulated upon treatment with the DNA-damaging agents doxorubicin and UV radiation, whereas p53-responsive promoter activity and expression of p21CIP1/WAF1 were strongly reduced in MCF7-Bcl-2 cells but not in MCF7-Bcl-2(Delta TM) or control MCF7 cells. The issue of membrane anchoring was further explored by testing the effects of Bcl-2 chimeric proteins that contained heterologous transmembrane domains from the mitochondrial protein ActA or the endoplasmic reticulum protein cytochrome b5. Both Bcl-2(ActA) and Bcl-2(Cytob5) suppressed p53-mediated transactivation of reporter gene plasmids with efficiencies comparable to wild-type Bcl-2. These results suggest that (a) Bcl-2 not only suppresses p53-mediated apoptosis but also interferes with the transcriptional activation of p53 target genes at least in some cell lines, and (b) membrane anchoring is required for this function of Bcl-2. We speculate that membrane-anchored Bcl-2 may sequester an unknown factor necessary for p53 transcriptional activity.

    INTRODUCTION
Top
Abstract
Introduction
References

Cell death is a physiological process that plays a major role in the maintenance of tissue homeostasis. Deregulation of the delicate balance of genes that encode proteins that either induce or inhibit cell death, contributes to the development of human neoplasia.

The bcl-2 gene was first discovered because of its involvement in the t(14;18) chromosomal translocations commonly found in lymphomas (1). Bcl-2 expression can also be altered in a variety of other cancers through various mechanisms, including loss of p53 tumor suppressor, which down-regulates Bcl-2 expression in some tissues (reviewed in Refs. 2 and 3). Bcl-2 functions as an inhibitor of cell death, thus contributing to cell expansion by inhibiting physiological cell turnover. Bcl-2 has also been shown to block cell death induced by a number of cytotoxic drugs as well as gamma -irradiation and is therefore believed to contribute to resistance to anticancer therapies (reviewed in Refs. 2 and 3). In vertebrates, several Bcl-2 homologues have been identified, some of which function as inhibitors (Bcl-XL, Mcl-1, and A1), and others as promoters of cell death (Bcl-XS, Bax, Bak, and BAD). These Bcl-2 family members are characterized by their ability to interact and form homo- and heterodimers (4). The relative abundance of anti- and proapoptotic Bcl-2 homologues determines the sensitivity of cells to apoptotic signals (reviewed in Refs. 2 and 5), but the mechanisms by which Bcl-2 inhibits cell death remain to be fully elucidated.

It has been proposed that Bcl-2 may inhibit cell death by interfering with the function of proapoptotic Bcl-2 homologues, by repressing the release of cytochrome c from mitochondria, by the sequestration of caspase activators, such as Apaf-1, by interfering with the production of free radicals by cytotoxic agents, or by regulating intracellular calcium homeostasis (for reviews, see Refs. 6-8). In addition, Bcl-2 has also been shown to bind and possibly modulate the function of other mammalian proteins, including R-Ras (9), Raf-1 (10), nuclear factor-kappa B (11), calcineurin (12), SMN (13), and the p53-binding protein 53BP2 (14). Interestingly, the Bcl-2 protein has a transmembrane C-terminal domain (TM)1 that targets it to intracellular membranes, most notably the outer membranes of mitochondria and nuclei and the endoplasmic reticulum membranes (15-17). Membrane anchorage appears to be required for optimal Bcl-2 function but may not be necessary for all of its antiapoptotic functions (18, 19).

The tumor suppressor p53 functions primarily as a transcription factor that controls genomic stability. The levels of p53 protein are normally very low but rise dramatically when DNA damage has occurred (20, 21). High levels of p53 protein cause cell cycle arrest, mostly in G1, or apoptosis depending of the cellular context and the gravity of the damage (22-24). The p53 gene is often deleted or mutated in cancer cells (25, 26). This leads to increased susceptibility to malignant transformation and blunted responses to DNA damaging cytotoxic agents (reviewed in Ref. 27). The functional status of p53 strongly correlates with its ability to bind specific DNA sequences on target genes and to activate transcription. In addition, p53 can repress transcription of some promoters lacking specific p53 binding sites, and it also possess some transcription-independent functions that are probably relevant to DNA-repair responses (28, 29). Among the genes that are activated by p53 are the cyclin-dependent kinase (cdk) inhibitor waf-1/p21 (30), cyclin G (31), GADD45 (32), the p53 inhibitor mdm2 (33), and the apoptosis-inducing genes bax (34) and KILLER/DR5 (35).

Interestingly, an inverse relationship has been found between mutated p53 and Bcl-2 expression in some types of carcinomas (36-39). This suggests that p53 and Bcl-2 may serve as inducer and repressor, respectively, of the same apoptotic pathway. Studies with bcl-2 transgenic mice and p53 knockout mice also support this concept (40). In this regard, it is well known that Bcl-2 is a potent inhibitor of p53-induced apoptosis (41, 42). In addition, in some cell systems, it has been demonstrated that Bcl-2 inhibits p53 translocation to the nucleus upon DNA damage (43) or when co-expressed with particular proteins (44). Bcl-2 may also relieve p53-mediated transcriptional repression (45, 46).

In this study, we report that high levels of Bcl-2 protein significantly impair p53-dependent induction of the cdk inhibitor p21CIP1/WAF1 after DNA damage in MCF7 breast cancer cells, without, however, blocking p53 nuclear import. In agreement with these findings, we show that Bcl-2 strongly inhibits p53-dependent transactivation of several promoters, including bax, p21CIP1/waf-1, mdm2, cyclin G, and GADD45 in transient co-transfection assays, again without preventing p53 entry into the nucleus. We also demonstrate that these inhibitory effects of Bcl-2 require its anchorage in intracellular membranes. These findings suggest that in some circumstances, Bcl-2 can block p53 function by inhibiting its transcriptional activity. Thus, Bcl-2 may be capable of interfering with p53 at several levels, probably depending on cell context.

    EXPERIMENTAL PROCEDURES

Plasmid Construction-- The plasmid pGL3-bax contains the p53 response element and TATA box from the BAX promoter cloned into BglII/HindIII sites of the pGL3enhancer reporter plasmid (Promega, Inc). The plasmid pCMV-Bcl-2(Delta TM) was generated by introducing a stop codon and XhoI site at position 562 of Bcl-2 cDNA (47) and then subcloning the HindIII/XhoI-digested fragment into HindIII/XbaI sites of pRc-CMV (Invitrogen, Carlsbad, CA). pCMV-Bcl-2(ActA) and pCMV-Bcl-2(Cb5) were generated by subcloning a HindIII-digested fragment from pSPUTK-Bcl-2(ActA) and -Bcl-2(Cyt5) (48) into HindIII sites of pcDNA3 (Invitrogen, CA). All plasmids were sequenced to confirm identity and correct orientation. Other plasmids employed here were previously described, including pCMV-Bcl-2 (49), pCMV-p53 (50), WWP-luc containing a 2-kb fragment of the waf-1 promoter (51), mdm2-luc containing 350 base pairs of the human mdm2 promoter (52), and pGL3-cyclinG-luc containing a 1.48-kb fragment of the cyclin G promoter (53). The control plasmid pGL3promoter, carrying the SV-40 early region promoter, and pGL3enhancer were purchased from Promega.

Cell Culture-- The human breast cancer cell line MCF7, transformed human embryonic kidney 293 cells, 293T, containing the large T antigen, and 293-EBNA cells, carrying the Epstain-Barr virus EBNA-1, were obtained from the American Type Culture Collection (Manassas, VA). Cells were maintained in a humidified atmosphere with 5% CO2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 1 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (Life Technology, Inc.). In some experiments, MCF7 cells were treated with 0.4 µM doxorubicin (Sigma).

Generation of MCF7-Bcl-2 Stable Transfectants-- MCF7 breast cancer cells (3 × 105) were plated in 60-mm dishes and grown overnight. For transfection, plasmid DNA (2 µg) was diluted into 0.1 ml of Opti-MEM medium (Life Technologies) and combined with 5 µl of LipofectAMINE (Life Technologies) in 0.1 ml of Opti-MEM. After incubation for 20 min, 0.8 ml of Opti-MEM was added, and the mixtures were overlaid onto cells. After 4 h, 1 ml of Opti-MEM containing 20% fetal calf serum was added to the cultures. The next day, medium was replaced with complete Dulbecco's modified Eagle's medium. Transformants were selected by growth for 14 days in complete medium containing 0.5 mg/ml G418 (Life Technologies). Polyclonal populations were grown and assayed for stable transgene expression by immunoblotting.

Transfections and Enzyme Assays-- Cells at 60% confluency were transfected by a standard calcium phosphate precipitate method. The total amount of plasmid DNA used was normalized to 2 µg/well and 7 µg/plate for transfections in 12-well and 6-cm plates, respectively, by the addition of empty plasmid. For reporter gene assays, 0.2 µg of the beta -galactosidase expression plasmid pCMV-beta -galactosidase was co-transfected with the luciferase reporter gene to normalize for variations in transfection efficiency. Cells were exposed to the precipitate for 5 h at 37 °C. For MCF7 cells, a glycerol shock was applied. Cells were exposed to 15% glycerol in HBS buffer (25 mM HEPES, pH 7.05, 0.75 mM Na2HPO4, 140 mM NaCl) for 4 min. The glycerol was removed by washing three times with PBS and replacement with fresh medium. For 293 cells, the medium was replaced without applying a shock. MCF7 stable cell lines were transfected using the lipofection method described above. Cell extracts were prepared 48 h after transfection. For reporter gene experiments, cells lysates were made as described by the manufacturer (Promega) and assayed for luciferase and beta -galactosidase activity. All transfection experiments were carried out in triplicate, repeated at least three times, and normalized for beta -galactosidase activity.

Cell Extracts and Subcellular Fractionation-- For gene expression experiments, cells were washed two times in PBS and lysed in RIPA buffer containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 0.28 TIU/ml aprotinin, 50 µg/ml leupeptin, 1 µM benzamidine, 0.7 µg/ml pepstatin). For protein localization experiments, nuclear and nonnuclear fractions were prepared according to the method of Schreiber et al. (54). Briefly, cells were collected and washed two times with ice-cold PBS. Cell pellets were resuspended in Buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2.5 mM dithiothreitol, protease inhibitors) and left on ice for 15 min prior addition of Nonidet P-40 to a final concentration of 0.6% (v/v). After centrifugation, supernatants were collected, and the nuclear pellets were washed two times in the same buffer. Pellets were finally resuspended in Buffer B (20 mM HEPES, pH 7.9, 400 mM NaCl, 25% glycerol, 0.1 mM EDTA, 0.1 mM EGTA, 2.5 mM dithiothreitol, protease inhibitors) and vigorously shaken for 10 min, and the postnuclear supernatants were cleared by centrifugation. Fractions were normalized for protein content based on the bicinchoninic acid method (Pierce) prior to the SDS-PAGE/immunoblot assay.

Immunoblotting-- Aliquots containing 25 or 35 µg of protein were subjected to SDS-PAGE using 12% gels, followed by electrotransfer to Immobilon-P transfer membranes (Millipore Corporation, Bedford, MA). Immunodetection was accomplished using 1:1000 (v/v) of anti-p53 (monoclonal Ab-1 and Ab-2 1:1, Oncogene Research Products, Cambridge, MA), anti-p21/WAF-1 (monoclonal Ab, PharMingen, La Jolla, CA) or anti-Bcl-2 (rabbit antiserum 1701) antibodies (54), followed by horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech). Detection was performed using the ECL detection method (Amersham Pharmacia Biotech).

Immunofluorescence Microscopy-- MCF7 stable transfectants were seeded into polylysine-coated 8-well chambers (Nalge-Nunc International) and grown overnight at 37 °C. Cells were then co-cultured in 0.4 µM doxorubicin for 20 h further. The cells were then washed, fixed with 3.7% formaldehyde in PBS for 10 min, rinsed with PBS, permeabilized with 0.15% Triton X-100 in PBS for 10 min, and blocked in a solution of 3% BSA in PBS/0.1% Triton X-100 for 1 h. The cells were then incubated with anti-p53 (1:50 monoclonal Ab-2, Oncogene Science Inc., San Diego CA), anti-p21 (1:50 monoclonal Ab-1, Oncogene Science Inc.) or anti-Bcl-2 (1:100 rabbit antiserum 1701) antibodies for 1 h. The slides were washed three times for 5 min in PBS and incubated with a 1:50 dilution (v/v) of fluorescein isothiocyanate-conjugated goat anti-mouse or TRITC-conjugated swine anti-rabbit immunoglobulin (Dako, Inc.). The washing step was repeated before applying coverslips using Vectashield® mounting medium (Vector Laboratories, Inc.).

    RESULTS

Bcl-2 Inhibits p53-dependent Transactivation of Target Genes-- To investigate the influence of Bcl-2 on the transactivation activity of p53, a co-transfection reporter gene assay was carried out. For these experiments, MCF7 breast cancer and human embryonic kidney 293T cells were transiently co-transfected with plasmids encoding wild-type p53 and Bcl-2, together with a reporter plasmid in which the luciferase gene is driven by a fragment of the human bax gene promoter containing its p53-response element and TATA box. As shown in Fig. 1, A and B, expression of wild-type p53 induced luciferase expression in both cell lines. Co-transfection of Bcl-2 strongly inhibited p53 transcriptional activity in a concentration-dependent manner in both cell lines, whereas co-transfection of a control protein (BAG-1L) did not affect p53 transactivation. To preliminarily explore the mechanisms responsible for the observed suppression of p53 transcriptional activity by Bcl-2, nuclear and cytoplasmic extracts were prepared from 293T transfected cells and tested for expression of p53 and Bcl-2 by immunoblotting. As shown in Fig. 1C, Bcl-2 had no obvious effects on total p53 protein levels. In addition, Bcl-2 also did not inhibit p53 accumulation in the nucleus, as has been reported in some but not all types of cells (41, 43-55). Tubulin staining was used to confirm the accuracy of the nuclear extraction procedure and to confirm loading of equivalent amounts of the samples. Similar results were obtained in MCF7 cells (data not shown). Taken together, these data indicate that Bcl-2 not only inhibits downstream events in p53-mediated apoptosis but, at least in certain cell lines, it also blocks p53 transcriptional activity.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Concentration-dependent repression of p53 transcriptional activity by Bcl-2. 293T embryonic kidney (A) and MCF7 breast cancer cells (B) were transiently transfected in 12- and 6-well plates, respectively, with a fixed amount of p53 (A, 0.5 µg; B, 1.5 µg), beta -galactosidase (A, 0.3 µg; B, 1.5 µg), and bax promoter luciferase (A, 0.5 µg; B, 1.5 µg) expression plasmids along with increasing amounts (A, 0-0.5 µg; B, 0.15-2 µg) of Bcl-2 or control plasmids. Two days after transfection, reporter gene activities were measured and expressed as a percentage of the average activity in the absence of Bcl-2 plasmid. In contrast to the T-antigen expressing 293 cells, p53 strongly induced apoptosis in the absence of Bcl-2 in MCF7 cells. The transcriptional activity under these conditions could therefore not be determined in these cells. C, Bcl-2 and p53 expression in transiently transfected 293T cells. Two days after transfection with 0.5 µg of p53, 0.4 µg of Bcl-2, and 1.6 µg of pRc-CMV, 293T cells were collected, and cytosolic (C) and nuclear (N) extracts were prepared. SDS-PAGE/immunoblot analysis was conducted using 25 µg of total protein per lane and antibodies specific for p53, Bcl-2 and tubulin.

Bcl-2 Suppresses p53-mediated Transactivation of Multiple p53-responsive Promoters-- To assess whether Bcl-2 affects the ability of p53 to transactivate promoters other than the bax gene promoter, similar experiments were performed using luciferase-expressing reporter constructs driven by the p53-responsive p21CIP1/WAF1, mdm2, or cyclin G promoters. As shown in Fig. 2, as with the bax promoter, Bcl-2 inhibited the p53-dependent transcriptional activity of all promoters, without, however, affecting their basal levels of activity. Under these same conditions, Bcl-2 did not impair the transactivation of the p53-independent SV40 early region promoter used as a control (Fig. 2). Thus, Bcl-2 specifically inhibits p53-mediated transactivation of target genes, apparently without significantly affecting transactivation by other transcription factors.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   Bcl-2 inhibits p53-mediated transactivation of multiple p53-responsive promoters. 293T cells were transiently transfected with p53, Bcl-2, and beta -galactosidase expression plasmids along with bax-luc, cyclinG-luc, wwp-luc, mdm2-luc, or pGL3-promoter reporter genes. Luciferase activity was measured 2 days after transfection. Results are expressed as luciferase relative to beta -galactosidase enzymatic activity (n = 3).

Inhibitory Effect of Bcl-2 Depends on Membrane Anchoring-- The C-terminal domain of Bcl-2 contains a stretch of hydrophobic amino acids that anchors the protein into cellular membranes (56, 57, 58). Previously, Bcl-2 has been found in association with mitochondrial membranes, the nuclear envelope and the endoplasmic reticulum (15-17). To assess the importance of the subcellular localization of Bcl-2 for the observed inhibitory effect on p53 transactivation, we compared p53 transcriptional activity in 293-EBNA cells transiently transfected with p53 and either wild-type Bcl-2 or a Bcl-2 mutant, which lacks the C-terminal TM domain. Interestingly, unlike Bcl-2, co-expression of Bcl-2(Delta TM) with p53 did not interfere with p53-mediated transactivation. In fact, this cytoplasmically distributed Bcl-2 deletion mutant slightly stimulated p53 activity, possibly by competing with endogenous Bcl-2 protein. Immunoblot analysis confirmed that the failure of Bcl-2(Delta TM) to suppress p53 was not attributable to lower levels of expression of the truncated protein compared with wild-type p53 (Fig. 3B).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Membrane anchoring is required for Bcl-2-mediated suppression of p53 transactivation. A, 293-EBNA cells were plated into 12-well plates and transiently transfected with 0.5 µg of p53, 0.5 µg of bax-luc, and 0.2 µg of beta -galactosidase expression plasmids, along with increasing amounts (0.05-0.5 µg) of plasmids encoding wild-type Bcl-2, Bcl-2(Delta TM), Bcl-2(ActA), or Bcl-2(Cb5). Reporter gene activities were measured two days after transfection and expressed as a percentage of the activity in the absence of Bcl-2 proteins (mean ± SD; n = 4). B, wild-type Bcl-2 and Bcl-2-chimeric protein expression in transiently transfected 293-EBNA cells was determined by immunoblotting. Two days after transfection with 0.5 µg of p53, 1.6 µg of pRc-CMV, and 0.4 µg of Bcl-2 or Bcl-2-mutant expression plasmids, cell lysates were prepared and SDS-PAGE/immunoblot analysis was conducted using 25 µg of total protein per lane and antibodies specific for Bcl-2.

The inability of the Bcl-2(Delta TM) mutant to suppress p53 transcriptional activity could be due either to a specific requirement for the TM domain of Bcl-2 or because of a need for membrane anchoring. To distinguish between these two possibilities, we examined the effects on p53 of Bcl-2 chimerical proteins in which the normal C-terminal TM domain was substituted with membrane-anchoring domains from proteins that reside in either the mitochondrial outer membrane (ActA) or the endoplasmic reticulum (cytochrome b5 (Cb5)) (48). Similar to wild-type Bcl-2, plasmids encoding either Bcl-2(ActA) or Bcl-2(Cb5) proteins caused a concentration-dependent suppression of p53-mediated gene transcription (Fig. 3A). The mitochondria-targeting Bcl-2(ActA) protein was somewhat more potent that the endoplasmic reticulum-targeting Bcl-2(Cb5) protein. Comparable levels of expression of the wild-type and mutant proteins were demonstrated by immunoblot analysis (Fig. 3B). Again, p53 protein production and nuclear localization were unaffected (data not shown). These observations indicate that the inhibitory effect of Bcl-2 on p53 transactivation requires its insertion into membranes.

Bcl-2 Inhibits p53-dependent p21/WAF-1 Up-regulation Following DNA Damage-- The role of Bcl-2 in p53-mediated transactivation of target genes induced following DNA damage was investigated using MCF7 breast cancer cells that had been stably transfected with plasmids encoding Bcl-2, Bcl-2(Delta TM) or no inserted cDNA (neo-control). Polyclonal cell populations expressing comparable levels of ectopic proteins were chosen for experiments (Fig. 4). First the effects of DNA damage on p53 protein levels were examined. Cells were exposed to 0.4 µM doxorubicin, and samples were harvested at different times. Nuclear and cytoplasmic extracts were prepared from each sample and subjected to immunoblot analysis for p53 expression. No p53 protein could be detected before cytotoxic treatment (data not shown). In contrast, as shown in Fig. 4A, p53 nuclear expression was strongly induced 24 h after doxorubicin treatment in MCF7 transfectants expressing either wild-type or mutant Bcl-2 protein, as well as in MCF7 control transfectants expressing only the neomycin resistance gene. Thus, as previously observed in transient transfection experiments (see above), the presence of high levels of Bcl-2 proteins did not interfere with p53 accumulation in the nucleus. Similar results were obtained for cells exposed to UV radiation (data not shown).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   Bcl-2 represses p21/WAF-1 induction in MCF7 cells following exposure to DNA damaging agents. Human MCF7 breast carcinoma cells were stably transfected with plasmids either encoding wild-type Bcl-2 (MCF7-Bcl-2), encoding Bcl-2 lacking the TM domain (MCF7-Bcl-2(Delta TM)), or carrying the neo-resistance gene alone (MCF7-Neo). Polyclonal populations expressing comparable levels of Bcl-2 and Bcl-2(Delta TM) were chosen for subsequent experiments. A, cells were treated with 0.4 µM doxorubicin. Cytosolic (Cyto) and nuclear (Nuclei) extracts were prepared 24 h later for analysis by immunoblotting using anti-p53 antibodies. B, cells were transiently cotransfected with a p53-responsive WWP-luciferase plasmid containing a 2-kb fragment of the p21/WAF-1 promoter and a beta -galactosidase expression plasmid used to normalize for transfection efficiency. One day after transfection, cells were treated with 0.4 µM doxorubicin or 10 J/m2 UV radiation. Cell extracts were prepared 24 h later and assayed for luciferase and beta -galactosidase enzyme activities. Results are expressed as a percentage of the maximal promoter activity measured in neo-control cells (mean ± S.D.; n = 3). C, Bcl-2 and p21 protein levels were assessed using lysates from stably transfected MCF7 cells before and after 24 h doxorubicin treatment. SDS-PAGE/immunoblot analysis was conducted using 35 µg of total protein per lane and antibodies specific for Bcl-2 and p21.

Next, to assess whether Bcl-2 also inhibits p53 transcriptional activity in the setting of DNA damage, MCF7 cells that stably expressed Bcl-2 or Bcl-2(Delta TM) were co-transfected with a p53-responsive luciferase reporter gene plasmid (wwp-luc), which contains a 2-kb fragment of the p21/waf-1 promoter. A beta -galactosidase expression plasmid was co-transfected to normalize for transfection efficiency. One day later, cells were treated with 0.4 µM doxorubicin or 10 J/m2 UV radiation. Cell extracts were prepared 24 h later and assayed for luciferase and beta -galactosidase enzyme activities. As shown in Fig. 4B, both doxorubicin and UV irradiation resulted in strong induction of the p21/waf-1 promoter in MCF7-Neo control cells. In contrast, transactivation of the p21/waf-1 promoter was reduced by ~70% in cells expressing high levels of Bcl-2. Unlike wild-type Bcl-2, MCF7 cells expressing Bcl-2(Delta TM) did not exhibit defects in their p53-mediated transactivation of the p21/waf-1 gene promoter after cytotoxic treatment (Fig. 4B). Cultures of UV-irradiated MCF7-Bcl-2 cells also became confluent, suggesting that cell proliferation was not inhibited despite treatment with DNA damaging agents. In contrast, cell cycle arrest was observed for Bcl-2(Delta TM) expressing cells (not shown).

To test whether the observed inhibition of the p53-mediated transactivation of a plasmid-borne p21/waf-1 promoter also applies to the endogenous p21/waf-1 gene, we examined the relative levels of p21 protein induction by immunoblot analysis of whole cell lysates prepared from MCF7 cells after exposure to DNA-damaging agents. As shown (Fig. 4C), p21 protein induction following treatment with doxorubicin was completely suppressed in MCF7-Bcl-2 but not in MCF7-Bcl2(Delta TM) cells. Fig. 4C also presents immunoblot analysis of the Bcl-2 and Bcl-2(Delta TM) proteins in stably transfected MCF7 cells, demonstrating that these two proteins were produced at comparable levels, thus excluding differences in their expression as a trivial explanation for the failure of Bcl-2(Delta TM) to suppress p21 protein induction.

Finally, similar observations were made by immunofluorescence microscopy, using antibodies specific for the Bcl-2, p53 or p21/WAF-1 proteins. As shown in Fig. 5A, the wild-type Bcl-2 protein was located in the nuclear envelope and perinuclear membranes, in a patter similar to that reported previously (15-17). In contrast, Bcl-2(Delta TM) was present diffusely through the cytosol and nucleus of MCF7 cells (Fig. 5B). Doxorubicin treatment resulted in marked up-regulation of p53 protein immunostaining in both MCF7-Bcl-2 and MCF7-Bcl-2(Delta TM) cells. In both lines, most of the p53 immunoreactivity was found in the nuclei of these cells (Fig. 5, C and D). Although p53 protein accumulated in the nuclei of doxorubicin-treated MCF7-Bcl-2 cells, expression of the p21/WAF-1 protein was not induced (Fig. 5E). In contrast, striking induction of nuclear p21/WAF-1 immunostaining was observed in MCF7-Bcl-2(Delta TM) cells (Fig. 5F). Thus, in agreement with the results obtained in transient transfection reporter gene assays, overexpression of Bcl-2 strongly reduced the induction of the p53 target gene p21/waf-1 after DNA damage, and this effect was again strictly dependent on the presence of the C-terminal membrane-anchoring domain of Bcl-2.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Bcl-2 but not Bcl-2(Delta TM) inhibits p53-dependent p21/WAF-1 protein induction following doxorubicin treatment. MCF7-Bcl-2 (A, C, and E) and MCF7-Bcl-2(Delta TM) (B, D, and F) stable transfectants were treated with 0.4 µM doxorubicin for 24 h. Cells were then fixed, permeabilized, and immunostained with antibodies specific for Bcl-2 (A and B), p53 (C and D) and p21 (E and F). Antibodies were detected by indirect immunofluorescence microscopy as described under "Experimental Procedures." Immunostaining of MCF7-Neo cells is not reported because of the high mortality of these cells when seeded into polylysine-coated 8-well chambers.

It is interesting to note that whereas MCF7-Neo cells died within 2 days after treatment, Bcl-2(Delta TM) and Bcl-2 transfectants survived for about 4 and over 7 days, respectively (data not shown). Thus, despite the inability of Bcl-2(Delta TM) to suppress p53-mediated transcriptional activity, it can apparently interfere with some downstream steps in the p53 pathway for apoptosis.

    DISCUSSION

The Bcl-2 oncoprotein is known to arrest p53-mediated apoptosis in many cell types by mechanisms that are still not fully elucidated. It has been demonstrated that Bcl-2 inhibits downstream apoptotic events, such as the release of cytochrome c from the mitochondria and subsequent activation of caspases (59, 60). However, Bcl-2 can also interfere with the activation of some transcription factors such as NFAT (12) and NF-kappa B (11), promoting us to explore whether Bcl-2 is also capable of regulating upstream events in the p53 pathway. The data provided here indicate that overexpression of Bcl-2 can suppress p53-mediated transactivation of p53 target genes. This effect was observed both in transient co-transfection reporter gene assays in which p53 was expressed from plasmids and in experiments in which endogenous p53 protein was activated by DNA-damaging agents. Thus, in addition to interfering with apoptotic events downstream of p53 target genes, Bcl-2 appears to be capable of suppressing an upstream step required for p53 function as a transcription factor.

We observed that anchoring of Bcl-2 to membranes is a requirement for its inhibitory effect on p53 transcriptional activity. Targeting of Bcl-2 to specific membrane compartments, such as endoplasmic reticulum and mitochondria, did not significantly alter the ability of Bcl-2 to inhibit p53. These observations are in agreement with the idea that at least some of the functions of Bcl-2 can be attributed to its ability to sequester cytosolic proteins at membranes (reviewed in Ref. 6). For instance, Bcl-2 was shown to inhibit NFAT-4 transcription factor signaling through sequestration of calcineurin, a phosphatase required for its dephosphorylation and subsequent nuclear translocation (12). A mutant of Bcl-2 lacking the membrane-anchoring domain still bound calcineurin but did not sequester it at membranes and did not suppress signaling through NFAT-4. Other reports have similarly described the recruitment of cytosolic proteins to internal membranes by overexpression of Bcl-2, including the protein kinase Raf1 (10) and the chaperone regulator BAG-1 (61).

The presence of the C-terminal membrane-anchoring domain has been reported to enhance the anti-apoptotic activity of Bcl-2 in most cellular contexts, but it may not be absolutely required at least for some of its functions (18, 19). In this regard, our observation that Bcl-2(Delta TM) had no inhibitory effect on p53 transactivation of target genes, but did partially suppress p53-induced apoptosis, indicates that some of the cell death protective functions of Bcl-2 are independent of its membrane insertion. These observations may be relevant to other reports that have demonstrated that targeting of Bcl-2 to different locations results in a preferential protection against distinct apoptotic stimuli (48).

In contrast to previous reports that examined a Myc-transformed erythroleukemia or prostate cancer cell lines (43, 44), in MCF7 and 293 cells, Bcl-2 did not inhibit the accumulation of p53 in the nucleus. Similarly, nuclear translocation of p53 is reportedly normal in a variety of other types of cell lines despite overexpression of Bcl-2 (40-42, 46, 57, 62). We therefore speculate that Bcl-2 reduces the capacity of p53 to transactivate genes by regulating the activity of p53 itself or by affecting transcriptional coactivators required for p53 function. For instance, Bcl-2 might directly inactivate p53 by regulating posttranslational modifications required for its function as a transcription factor. In this regard, p53 has been shown to be phosphorylated at multiple sites by different kinases, such as DNA-activated kinases (63), the protein kinases CKI and CK II (64, 65), cyclin-dependent kinases (66, 67), stress-activated kinases (68), mitogen-activated protein kinases (69), Raf-1 (70), and PKC (71). Phosphorylation status regulates p53 conformation and ability to transactivate target genes (72). As mentioned above, Bcl-2 interacts with some kinases and phosphatases, regulating their intracellular distribution. It is therefore conceivable that Bcl-2 indirectly regulates p53 function by sequestration of a kinase or phosphatase that phosphorylates or dephosphorylates p53. Alternatively, Bcl-2 might interact with transcriptional coactivators required by p53, inhibiting their entry into the nucleus. Interestingly, Bcl-2 and p53 have been reported to compete for binding to 53BP2 (14), a protein of unknown function that was initially discovered in a two-hybrid based screen for proteins that bind wild-type but not mutant p53 (73).

Recently, it has been demonstrated that p53 requires p300/CBP-family transcriptional co-activators for its transcriptional function (74). Proteins that disrupt this interaction, such as the E1a oncoprotein, reduce p53-dependent transactivation of the bax and p21/waf-1 promoters. Interestingly, Chawla et al. (75) recently reported that CBP contains a signal-regulated transcription activation domain that is controlled by nuclear calcium and calcium/calmodulin-dependent protein kinase IV. Calcium has also been shown to regulate p53 transcriptional activity under some circumstances (76-78). Because Bcl-2 has been reported to regulate calcium efflux from the endoplasmic reticulum under some circumstances (79) and prevent nuclear accumulation of calcium (80), it is conceivable that Bcl-2 might inhibit p53 transcriptional activity by hindering Ca2+-dependent CBP activation.

Whatever the mechanism responsible for the suppression of p53-mediated transcription by Bcl-2, comparison with other reports suggests that the overall importance of this action of Bcl-2 may be dependent on cell context. For instance, in hematopoietic cells, Bcl-2 overexpression has been reported to inhibit apoptosis induced by a temperature sensitive mutant allele of p53 without impairing its induction of G1 cell cycle arrest (62). Thus, in these cells, Bcl-2 apparently does not abrogate p53-mediated transcription of genes involved in inhibiting cell proliferation such as p21/waf-1. In contrast, Upadhyay et al. (81) reported that Bcl-2 overexpression can interfere with p53-mediated p21/WAF-1 induction in MCF10A breast cancer cells. Similarly, in some cell lines, it has been reported that Bcl-2 can inhibit p53-mediated repression of some promoters under circumstances where p53-mediated transactivation was unaffected (45, 46). We therefore speculate that Bcl-2 may have several potential mechanisms for interfering with specific steps of p53 activation or function and that the ultimate effect of overexpressing Bcl-2 may be dictated by the relative levels or differential expression of various p53 cofactors or regulators that Bcl-2 can perturb within cells. In summary, although much remains to be learned about the specific mechanisms involved, the observation that Bcl-2 inhibits p53-dependent transactivation of target genes might have important consequences for the response of cancer cells to cytotoxic treatments and thus contribute to the ability of Bcl-2 to promote chemo- and radioresistance.

    ACKNOWLEDGEMENTS

We thank Drs. M. Oren and S. Scheidtmann for the wwp-1-, mdm2-, and cyclinG-luciferase plasmids and T. Brown and E. Smith for help in manuscript preparation.

    FOOTNOTES

* This work was supported by the Swiss Science National Foundation, Cancer Research Switzerland Grant BIL KFS 19891995, Schweizerische Stiftung fuer Medizinisch-biologische Stipendien, and National Institutes of Health Grant CA55164-07.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel To whom correspondence should be addressed: The Burnham Institute, 10901 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-646-3140; Fax: 619-646-3194; E-mail: jreed{at}burnham-inst.org.

    ABBREVIATIONS

The abbreviations used are: TM, transmembrane domain; PBS, phosphate-buffered saline; PAGE, polyacrlamide gel electrophoresis; CMV, cytomegalovirus; kb, kilobase; Ab, antibody.

    REFERENCES
Top
Abstract
Introduction
References
  1. Tsujimoto, Y., Cossman, J., Jaffe, E., and Croce, C. M. (1985) Science 228, 1440-1443[Medline] [Order article via Infotrieve]
  2. Reed, J. C. (1994) J. Cell Biol. 124, 1-6[Medline] [Order article via Infotrieve]
  3. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewki, S., Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. (1996) J. Cell. Biochem. 60, 23-32[CrossRef][Medline] [Order article via Infotrieve]
  4. Yin, X. M., Oltvai, Z. N., and Korsmeyer, S. J. (1994) Nature 369, 321-323[CrossRef][Medline] [Order article via Infotrieve]
  5. Kroemer, G. (1997) Nat. Med. 3, 614-620[Medline] [Order article via Infotrieve]
  6. Reed, J. C. (1997) Nature 387, 773-776[CrossRef][Medline] [Order article via Infotrieve]
  7. Oltvai, Z. N., and Korsmeyer, S. J. (1994) Cell 79, 189-192[Medline] [Order article via Infotrieve]
  8. Green, D. R., and Reed, J. C. (1998) Science 281, 1309-1312[Abstract/Free Full Text]
  9. Fernandez-Sarabia, M. J., and Bischoff, J. R. (1993) Nature 366, 274-275[CrossRef][Medline] [Order article via Infotrieve]
  10. Wang, H. G., Rapp, U. R., and Reed, J. C. (1996) Cell 87, 629-638[Medline] [Order article via Infotrieve]
  11. Grimm, S., Bauer, M. K. A., Bauerle, P. A., and Schulze-Osthoff, K. (1996) J. Cell Biol. 134, 13-23[Abstract]
  12. Shibasaki, F., Kondo, E., Akagi, T., and McKeon, F. (1997) Nature 386, 728-731[CrossRef][Medline] [Order article via Infotrieve]
  13. Iwahashi, H., Eguchi, Y., Yasuhara, N., Hanafusa, T., Matsuzawa, Y., and Tsujimoto, Y. (1997) Nature 390, 413-417[CrossRef][Medline] [Order article via Infotrieve]
  14. Naumovski, L., and Cleary, M. L. (1996) Mol. Cell. Biol. 16, 3884-3892[Abstract]
  15. Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W., and Reed, J. C. (1993) Cancer Res. 53, 4701-4714[Abstract]
  16. Akao, Y., Otsuki, Y. S., Kataoka, S., Ito, Y., and Tsujimoto, Y. (1994) Cancer Res. 54, 2468-2471[Abstract]
  17. Chen-Levy, Z., Nourse, J., and Cleary, M. L. (1989) Mol. Cell. Biol. 9, 701-710[Medline] [Order article via Infotrieve]
  18. Tanaka, S., Saito, K., and Reed, J. C. (1993) J. Biol. Chem. 268, 10920-10926[Abstract/Free Full Text]
  19. Borner, C., Martinou, I., Mattmann, C., Irmler, M., Schaerer, E., Martinou, J. C., and Tschopp, J. (1994) J. Cell Biol. 126, 1059-1068[Abstract]
  20. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7491-7495[Abstract]
  21. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. (1993) Nature 362, 849-852[CrossRef][Medline] [Order article via Infotrieve]
  22. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. (1993) Cell 74, 957-967[Medline] [Order article via Infotrieve]
  23. Guillot, C., Falette, N., Paperin, M.-P., Courtois, S., Gentil-Perret, A., Treilleux, I., Ozturk, M., and Puisieux, A. (1997) Oncogene 14, 45-52[CrossRef][Medline] [Order article via Infotrieve]
  24. Ko, L., and Prives, C. (1996) Genes Dev. 10, 1054-1072[CrossRef][Medline] [Order article via Infotrieve]
  25. Vogelstein, B., and Kinzler, K. W. (1992) Cell 70, 523-526[Medline] [Order article via Infotrieve]
  26. Moll, U. M., Riou, G., and Levine, A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7262-7266[Abstract]
  27. Fisher, D. E. (1994) Cell 78, 539-544[Medline] [Order article via Infotrieve]
  28. Ewen, M. E., Oliver, C. J., Sluss, H. K., Miller, S. J., and Peeper, D. S. (1995) Genes and Dev. 9, 204-217[Abstract]
  29. Mosner, B., Mummenbrauer, T., Bauer, C., Sczakiel, G., Grosse, F., and Deppert, W. (1995) EMBO J. 14, 4442-4449[Abstract]
  30. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) Cell 75, 817-825[Medline] [Order article via Infotrieve]
  31. Okamoto, K., and Beach, D. (1994) EMBO J. 13, 4816-4822[Abstract]
  32. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. (1992) Cell 71, 587-597[Medline] [Order article via Infotrieve]
  33. Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993) EMBO J. 12, 461-468[Abstract]
  34. Miyashita, T., and Reed, J. C. (1995) Cell 80, 293-299[Medline] [Order article via Infotrieve]
  35. Wu, G. S., Burns, T. F., McDonald, E. R., 3rd, Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D. D., Zhou, J. Y., Muschel, R., Hamilton, S. R., Spinner, N. B., Markowitz, S., Wu, G., and el-Deiry, W. S. (1997) Nat. Genet. 17, 141-143[Medline] [Order article via Infotrieve]
  36. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. (1994) J. Natl. Cancer Inst. 86, 499-504[Abstract]
  37. Haldar, S., Negrini, M., Monne, M., Sabbioni, S., and Croce, C. M. (1994) Cancer Res. 54, 2095-2097[Abstract]
  38. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Angeletti, C. A., Basolo, F., and Bevilacqua, G. (1995) Br. J. Cancer 71, 1003-1007[Medline] [Order article via Infotrieve]
  39. McDonnell, T. J., Navone, N. M., Troncoso, P., Pisters, L. L., Conti, C., von Eschenbach, A. C., Brisbay, S., and Logothetis, C. J. (1997) J. Urol. 157, 569-574[Medline] [Order article via Infotrieve]
  40. Marin, M. C., Hsu, B., Meyn, R. E., Donehower, L. A., el-Naggar, A. K., and McDonnell, T. J. (1994) Oncogene 9, 3107-3112[Medline] [Order article via Infotrieve]
  41. Chiou, S.-K., Rao, L., and White, E. (1994) Mol. Cell. Biol. 14, 2556-2563[Abstract]
  42. Wang, Y., Szekely, L., Okan, I., Klein, G., and Wiman, K. G. (1993) Oncogene 8, 3427-3431[Medline] [Order article via Infotrieve]
  43. Beham, A., Marin, M. C., Fernandez, A., Herrmann, J., Brisbay, S., Tari, A. M., Lopez-Berenstein, G., Lozano, G., Sarkiss, M., and McDonnell, T. J. (1997) Oncogene 15, 2767-2772[CrossRef][Medline] [Order article via Infotrieve]
  44. Ryan, J. J., Prochownik, E., Gottlieb, C. A., Apel, I. J., Merino, R., Nunez, G., and Clarke, M. F. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5878-5882[Abstract]
  45. Shen, Y., and Shenk, T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8940-8944[Abstract]
  46. Sabbatini, P., Chiou, S. K., Rao, L., and White, E. (1995) Mol. Cell. Biol. 15, 1060-1070[Abstract]
  47. Sato, T., Hanada, M., Bodrug, S., Irie, S., Iwama, N., Boise, L. H., Thompson, C. B., Golemis, E., Fong, L., Wang, H.-G., and Reed, J. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9238-9242[Abstract/Free Full Text]
  48. Zhu, W., Cowie, A., Wasfy, G. W., Penn, L. Z., Leber, B., and Andrews, D. W. (1996) EMBO J. 15, 4130-4141[Abstract]
  49. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A., and Reed, J. C. (1995) Cell 80, 279-284[Medline] [Order article via Infotrieve]
  50. Unger, T., Mietz, J. A., Scheffner, M., Yee, C. L., and Howley, P. M. (1993) Mol. Cell. Biol. 13, 5186-5194[Abstract]
  51. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Nat. Genet. 1, 45-49[Medline] [Order article via Infotrieve]
  52. Juven, T., Barak, Y., Zauberman, A., George, D. L., and Oren, M. (1993) Oncogene 8, 3411-3416[Medline] [Order article via Infotrieve]
  53. Zauberman, A., Lupo, A., and Oren, M. (1995) Oncogene 10, 2361-2366[Medline] [Order article via Infotrieve]
  54. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. (1989) Nuleic Acids Res. 17, 6418[Medline] [Order article via Infotrieve]
  55. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Hoffman, B., Lieberman, D., and Reed, J. C. (1994) Oncogene 9, 1799-1805[Medline] [Order article via Infotrieve]
  56. Tsujimoto, Y., Ikegaki, N., and Croce, C. M. (1987) Oncogene 2, 3-7[Medline] [Order article via Infotrieve]
  57. Salvakumaran, M., Lin, H.-K., Miyashita, T., Wang, H.-G., Krajewski, S., Reed, J. C., Hoffman, B., and Liebermann, D. (1994) Oncogene 9, 1791-1798[Medline] [Order article via Infotrieve]
  58. Hockenbery, D. M., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. (1990) Nature 348, 334-336[CrossRef][Medline] [Order article via Infotrieve]
  59. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. (1997) Science 275, 1132-1136[Abstract/Free Full Text]
  60. Li, F., Srinivasan, A., Wang, Y., Armstrong, R. C., Tomaselli, K. J., and Fritz, L. C. (1997) J. Biol. Chem. 272, 30299-30305[Abstract/Free Full Text]
  61. Takayama, S., Krajewski, S., Krajewska, M., Kitada, S., Zapata, J. M., Kochel, K., Knee, D., Scudiero, D., Tudor, G., Miller, G. J., Miyashita, T., Yamada, M., and Reed, J. C. (1998) Cancer Res. 58, 3116-3131[Abstract]
  62. Wang, Y., Okan, I., Szekely, L., Klein, G., and Wiman, K. G. (1995) Cell Growth & Differ. 6, 1071-1075[Abstract]
  63. Lees-Miller, S. P., Sakaguchi, K., Ullrich, S. J., Appella, E., and Anderson, C. W. (1992) Mol. Cell. Biol. 12, 5041-5049[Abstract]
  64. Milne, D. M., Palmer, R. H., Campbell, D. G., and Meek, D. W. (1992) Oncogene 7, 1361-1369[Medline] [Order article via Infotrieve]
  65. Meek, D. W., Simon, S., Kikkawa, U., and Eckhart, W. (1990) EMBO J. 9, 3253-3260[Abstract]
  66. Bischoff, J. R., Friedman, P. N., Marshak, D. R., Prives, C., and Beach, D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4766-4770[Abstract]
  67. Milner, J., Cook, A., and Mason, J. (1990) EMBO J. 9, 2885-2889[Abstract]
  68. Milne, D. M., Campbell, L. E., Campbell, D. G., and Meek, D. W. (1995) J. Biol. Chem. 270, 5511-5518[Abstract/Free Full Text]
  69. Milne, D. M., Campbell, D. G., Caudwell, F. B., and Meek, D. W. (1994) J. Biol. Chem. 269, 9253-9260[Abstract/Free Full Text]
  70. Jamal, S., and Ziff, E. B. (1995) Oncogene 10, 2095-2101[Medline] [Order article via Infotrieve]
  71. Baudier, J., Delphin, C., Grunwald, D., Khochbin, S., and Lawrence, J. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11627-11631[Abstract]
  72. Lohrum, M., and Scheidtmann, K. H. (1996) Oncogene 13, 2527-2539[Medline] [Order article via Infotrieve]
  73. Iwabuchi, K., Bartel, P. L., Li, B., Marraccino, R., and Fields, S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6098-6102[Abstract]
  74. Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., and Livingston, D. M. (1997) Nature 387, 823-827[CrossRef][Medline] [Order article via Infotrieve]
  75. Chawla, S., Hardingham, G. E., Quinn, D. R., and Bading, H. (1998) Science 281, 1505-1509[Abstract/Free Full Text]
  76. Sebag, M., Gulliver, W., and Kremer, R. (1994) J. Invest. Dermatol. 103, 323-329[Abstract]
  77. Renzing, J., and Lane, D. P. (1995) Oncogene 10, 1865-1868[Medline] [Order article via Infotrieve]
  78. Scotto, C., Deloulme, J. C., Rousseau, D., Chambaz, E., and Baudier, J. (1998) Mol. Cell. Biol. 18, 4272-4281[Abstract/Free Full Text]
  79. Baffy, G., Miyashita, T., Williamson, J. R., and Reed, J. C. (1993) J. Biol. Chem. 268, 6511-6519[Abstract/Free Full Text]
  80. Marin, M. C., Fernandez, A., Bick, R. J., Brisbay, S., Buja, M. L., Snuggs, M., McConkey, D. J., von Eschenbach, A. C., Keating, M. J., and McDonnel, T. J. (1996) Oncogene 12, 2259-2266[Medline] [Order article via Infotrieve]
  81. Upadhyay, S., Li, G., Liu, H., Chen, Y. Q., Sarkar, F. H., and Choi Kim, H.-R. (1995) Cancer Res. 55, 4520-4524[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.